simvastatin has been researched along with oxidopamine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| McLachlan, C; Wang, PH; Wang, Q; Wong, PT | 1 |
| Chen, J; Deng, C; Hu, CH; Huang, XF; Long, L; Mackovski, N; Wang, Q; Wang, Y; Yang, Y; Zhu, C | 1 |
| Deng, C; Huang, XF; Wang, Q; Wu, A; Xiong, Z; Xu, Y; Yan, J; Yang, Y; Yang, YG; Yenari, MA; Ying, W; Zhang, L; Zhu, C | 1 |
| Gupta, A; Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| Gao, HM; Liu, M; Long, L; Pan, MQ; Tang, BS; Wang, Q; Wei, L; Xu, YQ; Yan, JQ; Zhou, P; Zhu, CS | 1 |
| Du, G; Fu, Q; Huang, L; Sun, J; Yan, J | 1 |
| Deng, C; Gao, H; Huang, XF; Li, J; Liao, J; Liu, X; Qin, B; Tang, B; Wang, Q; Wei, X; Yu, Y | 1 |
| Cao, X; Chen, Z; Shi, Q; Tang, B; Wang, T; Zhang, T | 1 |
| Chen, Z; Deng, C; Huang, XF; Liao, J; Liu, X; Mackovski, N; Meyer, BJ; Wang, Q; Wang, R; Wei, X; Weng, R; Xia, Y; Yu, Y | 1 |
| Brouwers, JF; Kalnytska, O; Martens, GJM; Wieringa, B; Xicoy, H | 1 |
10 other study(ies) available for simvastatin and oxidopamine
| Article | Year |
|---|---|
Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Down-Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medial Forebrain Bundle; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Recovery of Function; Simvastatin; Substantia Nigra; Sympatholytics; Treatment Outcome | 2005 |
Effects of simvastatin and 6-hydroxydopamine on histaminergic H1 receptor binding density in rat brains.
Topics: Animals; Brain; Male; Oxidopamine; Parkinsonian Disorders; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Histamine H1; Simvastatin | 2010 |
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses.
Topics: Animals; Anti-Inflammatory Agents; Anxiety; Apoptosis; Autoradiography; Cell Survival; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Glutamic Acid; Immunohistochemistry; L-Lactate Dehydrogenase; Male; Matrix Metalloproteinase 9; Nerve Degeneration; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Simvastatin; Substantia Nigra; Tritium; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2011 |
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
Topics: Amphetamine; Analysis of Variance; Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Malondialdehyde; Mitochondria; Motor Activity; NADH Dehydrogenase; Nitrites; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Simvastatin; Tetrazolium Salts; Thiazoles; Tumor Necrosis Factor-alpha | 2012 |
Simvastatin induces neuroprotection in 6-OHDA-lesioned PC12 via the PI3K/AKT/caspase 3 pathway and anti-inflammatory responses.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Caspase 3; Cyclooxygenase 2; Dopamine Plasma Membrane Transport Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Neuroprotective Agents; Oxidopamine; PC12 Cells; Phosphatidylinositol 3-Kinases; Phosphorylation; Rats; Signal Transduction; Simvastatin; Tumor Necrosis Factor-alpha | 2013 |
Simvastatin prevents neuroinflammation by inhibiting N-methyl-D-aspartic acid receptor 1 in 6-hydroxydopamine-treated PC12 cells.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Dose-Response Relationship, Drug; Glutamic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Oxidopamine; PC12 Cells; Rats; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Simvastatin; Sympatholytics; Time Factors | 2014 |
Simvastatin reverses the downregulation of M1/4 receptor binding in 6-hydroxydopamine-induced parkinsonian rats: the association with improvements in long-term memory.
Topics: Animals; Brain; Disease Models, Animal; Down-Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maze Learning; Memory, Long-Term; Muscarinic Antagonists; Oxidopamine; Parkinson Disease; Pirenzepine; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Simvastatin; Sympatholytics; Tritium | 2014 |
Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Male; MAP Kinase Signaling System; Oncogene Proteins v-fos; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Simvastatin; Time Factors | 2015 |
Reversal effect of simvastatin on the decrease in cannabinoid receptor 1 density in 6-hydroxydopamine lesioned rat brains.
Topics: Animals; Brain; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Simvastatin | 2016 |
Lipid Analysis of the 6-Hydroxydopamine-Treated SH-SY5Y Cell Model for Parkinson's Disease.
Topics: Cell Line, Tumor; Cholesterol; Humans; Lipidomics; Lipids; Models, Biological; Oxidopamine; Parkinson Disease; Simvastatin | 2020 |